Management of the Cutaneous Side Effects of Therapeutic Epidermal Growth Factor Receptor Inhibition

Publisher： Karger

E-ISSN： 2296-5262|33|8-9|470-479

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.33, Iss.8-9, 2010-07, pp. : 470-479

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Management of epidermal growth factor receptor tyrosine kinase inhibitor‐related cutaneous and gastrointestinal toxicities

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 14, Iss. 1, 2018-02 ,pp. : 23-31

John Wiley & Sons Inc

Access to resources Recommend Favorite

Epidermal Growth Factor Receptor Inhibition and Non-Small Cell Lung cancer

By von Eyben Finn  

Critical Reviews in Clinical Laboratory Sciences, Vol. 43, Iss. 4, 2006-08 ,pp. : 291-323

Informa Healthcare

Access to resources Recommend Favorite

Management of transitional cell carcinoma by targeting the epidermal growth factor receptor

By Brook Nicholas R   Colquhoun Alex J   Mellon J Kilian  

Therapy, Vol. 3, Iss. 3, 2006-05 ,pp. : 407-416

Future Medicine

Access to resources Recommend Favorite

Effects of the Anti-Epidermal Growth Factor Receptor Antibody Cetuximab on Cholangiocarcinoma of the Liver

By  

Oncology Research and Treatment, Vol. 30, Iss. 3, 2007-02 ,pp. : 129-131

Karger

Access to resources Recommend Favorite

Targeting the Epidermal Growth Factor Receptor in Colorectal Cancer: A Potential Therapeutic Role for Gastrin-Releasing Peptide Receptor Antagonists

By  

Oncology, Vol. 72, Iss. 3-4, 2007-12 ,pp. : 160-161

Karger

Access to resources Recommend Favorite